Navigation Links
Anxiety linked to newly diagnosed DCIS patients' overestimation of breast cancer risks
Date:2/12/2008

BOSTON--Elevated levels of anxiety may cause women with ductal carcinoma in situ (DCIS), the most common form of non-invasive breast cancer, to overestimate their risk of recurrence or dying from breast cancer, suggests a study led by researchers at Dana-Farber Cancer Institute in Boston.

"Although DCIS typically is very treatable disease, many women diagnosed with DCIS develop inaccurate risk perceptions," said Ann Partridge, MD, MPH, the study's lead author and a breast oncologist at Dana-Farber. "This exaggerated sense of risk needs to be addressed, as it may cause women to make poor treatment choices and adversely affect their emotional well-being and subsequent health behaviors."

The study's findings will be published online by the Journal of the National Cancer Institute on Feb. 12 and later in a print edition.

DCIS is characterized by the uncontrolled growth of cells within a breast's milk ducts. The risk of DCIS spreading elsewhere in the body is approximately 1 percent, and the risk of it recurring locally is 1 percent after mastectomy and less than 10 percent after breast-conserving surgery.

Approximately one fifth of all breast cancers diagnosed in the United States in 2006 were DCIS. The incidence of DCIS in the United States has increased the past 20 years, a jump that many attribute to the greater use of mammography screening. Partridge says that the growing number of DCIS cases underscores the need to develop a better understanding of how a DCIS diagnosis impacts womens emotional health.

The researchers conducted a longitudinal study of women who were recently diagnosed with DCIS to measure risk perceptions and its association with anxiety and depression. Of the 764 eligible participants, 487 completed the initial survey. Women were subsequently surveyed at nine months (426 completed) and at 18 months (392 completed).

More than half of the respondents to the initial survey (55 percent) thought they had at least a "moderate likelihood" of their DCIS recurring within five years of diagnosis, and 68 percent thought it was at least moderately likely to recur within their lifetime. More than one in four (28 percent) responded it was at least moderately likely that the DCIS would spread elsewhere in the body. The participants' risk perceptions remained statistically unchanged over the studys 18-month span.

The psychosocial and quality of life assessments indicated that anxiety was most consistently associated with a womans misperceptions of elevated risk. Specifically, a woman with heightened anxiety was more likely to think that her DCIS would recur within five years or that it would become invasive breast cancer within five years or sometime during her lifetime.

Partridge says the study's findings pose a "chicken and the egg" conundrum. "Are women with higher anxiety more likely to misperceive their risk, or are women somehow developing inaccurate risk perceptions and thus developing anxiety? I'm not sure that question can be answered at this point." She says the findings underscore the need and importance of better doctor-patient communications, and the need for further research in this area.

"Some of the anxiety is clearly tied to our societys fears about breast cancer," explains Partridge, who is also an assistant professor of medicine at Harvard Medical School. "A woman may also have multiple care providers -- medical oncologist, surgeon, plastic surgeon, internist -- and may hear mixed messages about her risks. Improved understanding of DCIS on the part of the medical community may also help women make better, more informed decisions about their care."


'/>"/>

Contact: Bill Schaller
william_schaller@dfci.harvard.edu
617-632-5357
Dana-Farber Cancer Institute
Source:Eurekalert

Related medicine news :

1. 40 Million Americans Endure Anxiety Everyday
2. Depression and anxiety can double chances of heart ailments
3. Anxiety Raises Heart Attack Risk
4. Ambien CR(R) (zolpidem tartrate extended-release) tablets CIV Improved Chronic Insomnia in Patients with Co-Morbid Generalized Anxiety Disorder
5. Walk away menopausal anxiety, stress and depression
6. Religion habit cuts anxiety in women
7. Massage Eases Pain, Anxiety After Surgery
8. Smaller babies more prone to depression, anxiety later on
9. Drinking away anxiety -- a new program finds safer ways for college students to cope
10. Diet Drug Rimonabant Tied to Depression, Anxiety
11. Stress and Anxiety Interfere With Sleep
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 2016 , ... Austin residents seeking Mohs surgery services, can now turn to ... Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to ... fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Comfort Keepers® of ... Cancer Society and the Road To Recovery® program to drive cancer patients to and ... other adults to ensure the highest quality of life and ongoing independence. Getting ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative ... has initiated cultivation and processing operations at its production facility, and opened its ... Puradigm is the manufacturer of a complete system of proactive air and surface ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/26/2016)... 2016 Story Highlights: ... within the health care industry is causing providers to ... , Deloitte offers a suite of solutions for health ... efficient cost optimization: labor resource analysis, revenue cycle optimization ... better outcomes and better economics ...
(Date:6/24/2016)... , June 24, 2016  Collagen Matrix, Inc., ... development and manufacturing of collagen and mineral based ... today that Bill Messer has joined ... to further leverage the growing portfolio of oral ... Bill joins the Collagen Matrix executive ...
Breaking Medicine Technology: